Patent application number | Description | Published |
20100212803 | SYSTEMS AND METHODS OF REINFORCING A PIPE USING FIBER BUNDLES - A method of reinforcing a pipe or other structure using fiber reinforced polymer includes coating a raw carbon and/or other types of fiber roving with an epoxy or other resin, selectively directing the fiber roving through a positioning assembly of a reinforcing system, splaying the fiber roving that exits the positioning assembly onto a pipe wall or other surface, rotating the positioning assembly about an axis to place splayed fiber roving along a first circumferential section of the pipe wall or other surface and moving the positioning assembly along a longitudinal axis of the pipe or other structure to selectively place splayed fiber roving along a second circumferential section of the wall. | 08-26-2010 |
20100218708 | METHODS OF REINFORCING STRUCTURES AGAINST BLAST EVENTS - A method of reinforcing a structural member comprises positioning a shell around the structural member, placing a force dampening material around an exterior of the shell and securing the force dampening material around the shell. In certain arrangements, the method further includes at least partially filling a space defined between the structural member and the shell with a filler material. In some embodiments, the filler material comprises a concrete, a grout, an epoxy, combinations thereof and/or the like. In one embodiment, the shell comprises a fiber reinforced polymer (e.g., CFRP, GFRP, aramid fibers, epoxy, other resins, etc.). In alternative embodiments, the methods additionally includes placing one or more layers of fiber reinforced polymer around the shell prior to placing a force dampening material around an exterior of the shell. In some embodiments, the layer of fiber reinforced polymer comprises CFRP, GFRP or any other type of fiber reinforced polymer. | 09-02-2010 |
20120058338 | SYSTEMS AND METHODS FOR PROTECTING CABLES AND OTHER STRUCTURAL MEMBERS - According to some embodiments, a cable protection system to at least partially shield a cable from heat, fire, an impact or other potentially harmful event or occurrence comprises a first encompassing member configured for placement around the cable or cable bundle, wherein a first void is defined between the first encompassing member and an outside of the cable or cable bundle. The system additionally includes a second encompassing member positioned around the first encompassing member, wherein a second void is defined between the first encompassing member and the second encompassing member. Further, the system comprises one or more fill materials positioned within the second void. In some embodiments, the fill material comprises vermiculite, ceramic and/or one or more other materials. The first void permits the cable protection system to be slidably moved relative to the cable or cable bundle. | 03-08-2012 |
Patent application number | Description | Published |
20130309013 | REINFORCEMENT SYSTEM FOR INCREASED LATERAL STABILITY OF FLOOD WALL - Reinforcement system for concrete panel wall, such as I-type flood wall, includes high tensile strength textile attached to wall by adhesive and reinforced by mechanical fasteners. Most preferred embodiment comprises a strip of fiber reinforced plastic spanning multiple panels, with the grain of the textile material extending horizontally. Alternative embodiment includes vertical FRP with bias-grain textile. Fasteners are preferably ductile fiber anchors. | 11-21-2013 |
20140034175 | EXPANDABLE LINER FOR THE PROTECTION AND STRENGTHENING OF EXISTING PIPES - A method of lining an interior of a pipe in need of repair comprises providing a carrier tube having one or more expandable materials, coating the carrier tube with a binder, securing one or more layers of a fiber-laden material along an exterior surface of the carrier tube with the assistance of the binder. The carrier tube is delivered, together with the at least one layer of the fiber-laden material and the binder, to a targeted location inside a pipe in need of repair. The carrier tube comprises a first diameter while the carrier tube is being delivered to the targeted located inside the pipe in need of repair. The method additionally comprises radially expanding the carrier tube from the first diameter to a second diameter, such that the one or more layers of the fiber-laden material and the binder at least partially contact and/or adhere to an interior wall of the pipe. | 02-06-2014 |
20150323118 | EXPANDABLE LINER FOR THE PROTECTION AND STRENGTHENING OF EXISTING PIPES - A method of lining an interior of a pipe in need of repair comprises providing a carrier tube having one or more expandable materials, coating the carrier tube with a binder, securing one or more layers of a fiber-laden material along an exterior surface of the carrier tube with the assistance of the binder. The carrier tube is delivered, together with the at least one layer of the fiber-laden material and the binder, to a targeted location inside a pipe in need of repair. The carrier tube comprises a first diameter while the carrier tube is being delivered to the targeted located inside the pipe in need of repair. The method additionally comprises radially expanding the carrier tube from the first diameter to a second diameter, such that the one or more layers of the fiber-laden material and the binder at least partially contact and/or adhere to an interior wall of the pipe. | 11-12-2015 |
Patent application number | Description | Published |
20120087915 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 04-12-2012 |
20120100138 | THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 04-26-2012 |
20120183535 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 07-19-2012 |
20130195852 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 08-01-2013 |
20130202611 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 08-08-2013 |
20130273030 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 10-17-2013 |
20130310402 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 11-21-2013 |
20140194446 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 07-10-2014 |
20140303191 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor. | 10-09-2014 |
20150031710 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 01-29-2015 |
20150031711 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 01-29-2015 |
Patent application number | Description | Published |
20130090386 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 04-11-2013 |
20130095067 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE - The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal. | 04-18-2013 |
20130231342 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE - The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). | 09-05-2013 |
20130289076 | CYCLOPROPYLAMINE INHIBITORS OF OXIDASES - The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. | 10-31-2013 |
20140163041 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS - The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. | 06-12-2014 |
20140213657 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 07-31-2014 |
20140256729 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS - The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. | 09-11-2014 |
20150025054 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS - The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. | 01-22-2015 |
20150119396 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS - The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. | 04-30-2015 |
20150232436 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS - The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders. | 08-20-2015 |